CSIMarket
 


Agenus Inc  (AGEN)
Other Ticker:  
 
 

AGEN's Operating Income Growth by Quarter and Year

Agenus Inc's Operating Income results by quarter and year




AGEN Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -57.76 -54.03 -21.71
III Quarter September -46.34 -41.65 187.54 -34.79
II Quarter June -54.67 -44.57 -66.40 -33.27
I Quarter March -54.34 -35.46 -41.37 -27.46
FY   -155.35 -179.44 25.74 -117.23



AGEN Operating Income third quarter 2023 Y/Y Growth Comment
Agenus Inc in the third quarter 2023 recorded Operating Loss of $ -46.34 millions.

According to the results reported in the third quarter 2023, Agenus Inc achieved the best Operating Income growth in Biotechnology & Pharmaceuticals industry. While Agenus Inc' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2023.

Explain Operating Income growth


AGEN Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Agenus Inc's third quarter 2023 Operating Income $ -46.34 millions AGEN's Income Statement
Agenus Inc's third quarter 2022 Operating Income $ -41.65 millions Quarterly AGEN's Income Statement
New: More AGEN's historic Operating Income Growth >>


AGEN Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Agenus Inc's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AGEN's III. Quarter Q/Q Operating Income Comment
Even if Agenus Inc in the III. Quarter 2023 showed Operating Loss of $ -46.34 millions, it should be said, that this are slight up side in contrast to the -54.67 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Agenus Inc achieved highest sequential Operating Income growth. While Agenus Inc's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AGEN's III. Quarter Q/Q Operating Income Comment
Even if Agenus Inc in the III. Quarter 2023 showed Operating Loss of $ -46.34 millions, it should be mentioned, that those numbers are improvement compare to the -54.67 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Agenus Inc achieved highest sequential Operating Income growth. While Agenus Inc's Operating Income growth quarter on quarter, overall rank is .


Agenus Inc's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ -213.10 $ -208.41 $ -198.31 $ -179.43 $ -175.70
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Agenus Inc' has realized cumulative trailing twelve months Operating Loss of $ -213 millions in the Sep 30 2023 period.
The situation is getting worse as the cumulative Operating Loss is inflating from $ -208.41 millions in TTM ending quarter Jun 30 2023 and $ 53.487 millions for the twelve months ending in the quarter a year ago.

Agenus Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Agenus Inc' has realized cumulative trailing twelve months Operating Loss of $ -213 millions in the Sep 30 2023 period.
The business is detiriorating as the cumulative Operating Loss is inflating from $ -208.41 millions for the period from Jun 30 2023 to Sep 30 2022 and $ 53.487 millions for the twelve months ending in the quarter a year ago Claudio Monteiro wrote.

Agenus Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
AGEN's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for AGEN's Competitors
Operating Income Growth for Agenus Inc's Suppliers
Operating Income Growth for AGEN's Customers

You may also want to know
AGEN's Annual Growth Rates AGEN's Profitability Ratios AGEN's Asset Turnover Ratio AGEN's Dividend Growth
AGEN's Roe AGEN's Valuation Ratios AGEN's Financial Strength Ratios AGEN's Dividend Payout Ratio
AGEN's Roa AGEN's Inventory Turnover Ratio AGEN's Growth Rates AGEN's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Biomx Inc 19.03%$ 19.026 millions
Shockwave Medical Inc 18.66%$ 18.660 millions
Intuitive Surgical Inc 16.77%$ 16.771 millions
Nature s Sunshine Products inc 16.36%$ 16.361 millions
Align Technology inc 15.79%$ 15.795 millions
Stryker Corp15.22%$ 15.223 millions
Encompass Health Corporation14.02%$ 14.021 millions
Idexx Laboratories Inc12.44%$ 12.439 millions
Envista Holdings Corporation11.81%$ 11.812 millions
Surgery Partners Inc 11.47%$ 11.471 millions
Medpace Holdings Inc 9.10%$ 9.098 millions
Zoetis Inc 9.07%$ 9.066 millions
Zimmer Biomet Holdings Inc 8.68%$ 8.683 millions
Amedisys Inc 8.43%$ 8.425 millions
Hca Healthcare Inc 7.79%$ 7.787 millions
Chemed Corporation7.41%$ 7.412 millions
Ensign Group Inc7.41%$ 7.410 millions
Dariohealth Corp 6.68%$ 6.677 millions
U S Physical Therapy Inc6.62%$ 6.620 millions
Halozyme Therapeutics Inc 5.99%$ 5.987 millions
Gamida Cell Ltd 5.73%$ 5.727 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com